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cost-effectiveness analysis. Initial responses suggest that manufacturers will accept the 
challenge to improve the quality of available evidence to support future decisions.
CASE3
THE VA TECHNOLOGY ASSESSMENT ADVISORY GROUP:  
INFORMING EVIDENCE-BASED POLICY RECOMMENDATIONS FOR 
ROBOTIC PROSTATECTOMY
Adams E
Veterans Health Administration, Boston, MA, USA
ORGANIZATION: Veterans Health Administration (VHA) Ofﬁce of Patient Care 
Services provides policy and program development and oversight of clinical care 
delivered to 7.8m veterans nationally. PROBLEM OR ISSUE ADDRESSED: Should 
VHA adopt robotic prostatectomy (RP) for use in clinical care? If so, how should it 
be implemented? GOALS: (1) Apply a new health technology assessment (HTA) 
process for evaluating FDA-approved non-IT and non-pharmacologic new and emerg-
ing health care technologies that draws upon a wide range of VHA expertise as well 
as clinical research. (2) Make policy recommendations on the need, purchase, and 
implementation of these technologies in VHA clinical care in a timely fashion. OUT-
COMES ITEMS USED IN THE DECISION: Available clinical efﬁcacy/effectiveness, 
cost-effectiveness and safety data from the literature, regulatory status, utilization and 
cost analysis (UCA). IMPLEMENTATION STRATEGY: The Technology Assessment 
Advisory Group (TAAG) applied input from HTA, a clinical expert panel and a utiliza-
tion and cost analysis to make evidence-based recommendations on the acquisition, 
use and funding of RP in VA. RESULTS: As of 2006 evidence from heterogeneous 
case series demonstrated the safety and feasibility of RP. Its clinical use was limited 
by: high initial investment and operating costs; substantial training requirements; and 
lack of multicenter experience and clinical trial data from which to determine effective-
ness and cost-effectiveness relative to current practices. The impact of RP on the design 
and work processes in the surgical theater was also unclear. Fulﬁlling research and 
education missions and enhancing prestige and proﬁt were the primary motivators to 
its technological diffusion. UCA showed that patient recapture estimates of $13,000/
year would not offset the costs unique to the robotic system, and therefore, would 
not be economically viable. There are insufﬁcient research data and cost beneﬁt to 
justify widespread purchase and implementation of this technology solely for RP. 
Cautious diffusion to centers of excellence with skills and infrastructure to support 
the technology was recommended, as were options to help defray costs such as leasing 
the robotic system, providing training to outsiders and/or providing this option to the 
Dept of Defense. LESSONS LEARNED: The TAAG process proved feasible and effec-
tive in supporting informed and timely policy recommendations for the purchase and 
use of RP in a manner that enhances quality of care in a environment of cost-contain-
ment. After a one-year moratorium, VHA guidance was created to help individual 
facilities make an informed make or buy decision based on demonstration of an 
appropriate infrastructure in place to support training, backup, maintenance, and 
outcome data collection. The guidance included site visit and approval from the VHA 
National Surgery Program with oversight of outcome data collection, which continues 
today.
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NEW FINDINGS FROM INTEGRATING ADMINISTRATIVE AND 
FINANCIAL DATABASES TO ESTIMATE PRICE OF HOSPITALIZATIONS
Wong H1, Levit K2, Sun YC3
1Agency for Healthcare Research and Quality, Rockville, MD, USA, 2Thomson Reuters, 
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ORGANIZATION: Agency for Healthcare Research and Quality (funding organiza-
tion), Thomson Reuters PROBLEM OR ISSUE ADDRESSED: Hospital administrative 
data have been used in “cost-effectiveness,” “cost-beneﬁt,” and “burden-of-illness” 
studies because they contain large numbers of cases for speciﬁc conditions and pro-
cedures and because charge information is available. While these data generally 
contain information on how much the facility charged for the hospital stay, they lack 
information on the cost to provide care and the amount reimbursed for care. In the 
past, AHRQ developed a set of hospital-level cost-to-charge ratios to estimate the cost 
of providing care. AHRQ is piloting a project to create price-to-charge ratios that will 
be used in conjunction with charge information collected on hospital discharge records 
to estimate the “price” of inpatient hospital care. The term “price” reﬂects the amount 
that hospitals are paid by insurers and consumers based on payer revenue information 
for each hospital. This is the amount of revenue that hospitals actually receive, net of 
any discounts negotiated with insurers. These ratios have been linked to the Healthcare 
Cost and Utilization Project (HCUP) State Inpatient Databases (SID) for 5 states. The 
HCUP SID ﬁles contain the universe of inpatient discharge abstracts (including infor-
mation on charges) in participating States, translated into a uniform format to facili-
tate multi-State comparisons and analyses. Currently, 40 states participate in HCUP, 
encompassing about 90 percent of all U.S. community hospital discharges. The 
impetus for this project is to make health care information more transparent to con-
sumers. While the addition of price information will help consumers make more 
informed choices about hospitalizations for themselves and their families, this infor-
mation will also be valuable for researchers by providing alternatives to measuring 
resource use that are better suited for their studies. This presentation builds on last 
year’s talk by presenting price results for 5 states. GOALS: The short-term goals of 
this project include: · Estimate prices by payer (Medicare, Medicaid, Private, and 
Self-pay) for common diagnoses in 5 states for 2006 · Assess the credibility of esti-
mated prices (“proof-of-concept”) · Evaluate price differences for major payers, geo-
graphic areas, and common diagnoses. The long term goals of this project include: · 
Extend study to a total of 10 states · Create models to estimate prices for HCUP states 
not included in the pilot · Provide states with information on hospital average prices 
that can be used to populate a Website where consumers can explore pricing for 
common diagnoses · Release prices publicly on AHRQ databases to explore inpatient 
pricing by market area to address research issues such as competition among hospitals, 
pricing differentials between payers, relationship between prices and quality, and 
effects of hospital entry on prices. OUTCOMES ITEMS USED IN THE DECISION: 
HCUP data have been used in “cost-effectiveness,” “cost-beneﬁt,” and “burden-of-
illness” studies because they contain large numbers of cases for speciﬁc conditions and 
procedures and because charge and estimated cost information is available. The addi-
tion of estimated prices will provide researchers an additional tool to more effectively 
conduct their studies. IMPLEMENTATION STRATEGY: AHRQ solicited participa-
tion of HCUP Partner organizations that have access to hospital revenue information 
by payer and are willing to release state-level charge and price information broken 
out by the four broad payer groups and broad diagnostic categories. Initially, AHRQ 
is utilizing information from 5 HCUP SID Partner States in conjunction with hospital-
speciﬁc revenue information to develop prices for hospitalizations. RESULTS: Prices 
have been estimated for 5 states. We show the consistency and reasonableness of 
estimated prices by presenting the average prices of speciﬁc diagnosis by payers, states, 
and metropolitan areas. In addition, average prices by bed-size, teaching status, and 
hospital ownership are examined. One important advantage of using “prices” rather 
than “costs” or “charges” is that prices are speciﬁc to each payer group, reﬂecting the 
sum of contractual and other adjustments. We demonstrate the differences in resource 
use as measured by “charges,” “costs,” and “prices.” An explanation of what these 
concepts will be discussed. LESSONS LEARNED: To date, the lessons learned include: 
1. The number of States that collect ﬁnancial information by major payers for each 
hospital is limited. 10 States have been identiﬁed with most of the detailed information 
required. 2. While States may collect gross and net revenue information by payer, not 
all separate these revenues completely for inpatient and outpatient services and for 
the major payer groups. Estimating methods have been developed to address these 
issues. 3. Deﬁnitions of revenues and the level of detailed data collection vary consider-
ably among States and needs to be reconciled.
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ADHERENCE, DISCONTINUATION, AND SWITCHING OF BIOLOGIC 
THERAPIES IN MEDICAID ENROLLEES WITH RHEUMATOID ARTHRITIS
Li P, Blum MA, Feldt JMV, Hennessy S, Doshi JA
University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVES: Biological therapies are an expensive but important advance in the 
management of RA. The potential therapeutic beneﬁts of biologics demonstrated in 
clinical trials may be undermined by poor adherence and early discontinuation of 
treatment (i.e., non-persistence) in clinical practice. This study examined adherence, 
discontinuation, and switching of Rheumatoid Arthritis (RA) biologics over a one year 
period following initiation of the biologic treatment in Medicaid patients with RA. 
METHODS: The study sample consisted of Medicaid patients with RA in California, 
Florida and New York who had newly initiated etanercept (n = 1359), anakinra (n = 
267), or inﬂiximab (n = 1012) between January 1, 2000 and December 31, 2002. 
Adherence (proportion of days covered (PDC) ≥ 0.80), discontinuation (90-day con-
tinuous gap), and switching (initiation of second biologic within 90 days of discontinu-
ation date of index biologic) were measured during the 12-months post-index biologic 
initiation. Sensitivity analyses were conducted by varying the thresholds to deﬁne these 
measures. Logistic regressions examined the factors associated with RA biologic 
adherence and discontinuation. RESULTS: Anakinra users had the lowest mean PDC 
(0.36) and percent adherent patients (10.5%) followed by etanercept users (mean 
PDC:0.57; % adherent:32%) and inﬂiximab users (mean PDC:0.64; % adher-
ent:43%). All three groups had high discontinuation rates (41% etanercept, 76% 
anakinra, and 41% inﬂiximab). Few patients who discontinued the index biologic 
switched to another biologic (0.2% to 9%). Logistic regressions found that patients 
in Florida had lower odds of being adherent and higher odds of discontinuing their 
index biologic than patients in California. Consistent with descriptive results, 
Anakinra users had lower odds and inﬂiximab users had higher odds of being adherent 
than etanercept users. Anakinra users had higher odds of discontinuation than etan-
ercept users. CONCLUSIONS: This study highlights poor adherence and premature 
discontinuation without concurrent switching of RA biologics that should raise 
concern for clinicians as well as payers.
CM2
EFFECTS OF NONADHERENCE WITH ANGIOTENSIN CONVERTING 
ENZYME INHIBITORS/ANGIOTENSIN RECEPTOR BLOCKERS ON 
HOSPITALIZATION AND MORTALITY AMONG PATIENTS WITH 
DIABETES
Yang Y1, Banahan BF1, Pace PF2
1University of Mississippi, University, MS, USA, 2University of Mississippi, Oxford, MS, USA
OBJECTIVES: The objective was to determine the effect of nonadherence to angio-
tensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) and 
subsequent diabetes-related hospitalization and mortality among patients with diabe-
tes enrolled in a state Medicaid program. METHODS: This is a retrospective cohort 
study of patients with diabetes using Medicaid pharmacy and medical claims data. 
